Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.

Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27.

2.

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.

Pothuri B.

Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307. Review.

PMID:
24131965
3.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
4.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
5.

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Bouwman P, Jonkers J.

Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Review.

6.

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.

Walsh CS.

Gynecol Oncol. 2015 May;137(2):343-50. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25. Review.

7.

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Vollebergh MA, Jonkers J, Linn SC.

Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16. Review.

PMID:
21922196
8.

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.

Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL.

Asia Pac J Clin Oncol. 2011 Sep;7(3):197-211. doi: 10.1111/j.1743-7563.2011.01430.x. Review.

PMID:
21884432
9.

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Tewari KS, Eskander RN, Monk BJ.

Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13. Review.

10.

The role of PARP inhibitors in the treatment of ovarian carcinomas.

Tinker AV, Gelmon K.

Curr Pharm Des. 2012;18(25):3770-4. Review.

PMID:
22591423

Supplemental Content

Support Center